Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

User has seborrhoeic dermatitis causing hair loss. They are using Ketoconazole shampoo and may use selenium sulfide shampoo.

A user's experience with hair loss treatments, including finasteride and other options such as RU58841, Nizoral, Pumpkin Seed, and Adenosine; the importance of being in a positive frame of mind when considering taking finasteride; and the need to address life issues before starting finasteride.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Finasteride can aid hair regrowth but may cause side effects like depression and sexual dysfunction. Users discuss experiences with finasteride, minoxidil, and RU58841, highlighting varied responses and the importance of informed treatment choices.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

The user has been using Finasteride for seven months to address hair loss but hasn't seen noticeable regrowth and is experiencing brittle, thinning hair with scalp issues. They are also using Salisia and Re’equil Salicylic Acid shampoo for potential psoriasis and are seeking advice from others with similar experiences.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

A person with hair loss due to seborrheic dermatitis saw improvement after treating the condition and using 5mg oral minoxidil, topical minoxidil, collagen, biotin, and vitamins. They are asking if the progress is real, and others have noted the oral minoxidil as a significant treatment.

Users discuss whether Koshine reduces sebum and scalp itchiness. Some report reduced sebum and seborrheic dermatitis, while others debate the effectiveness of anti-androgens like RU58841 for hair loss.

The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

RU58841 treatment for hair loss, comparing premixed solutions to powder form. Users prefer powder for cost-effectiveness and customization.

The conversation discusses hair loss treatments, specifically oral minoxidil (2.5mg), dutasteride (0.5mg every other day), and ketoconazole. The user reports slow progress but significant hair growth after adding ketoconazole to their routine.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

A 23-year-old male shares his positive progress using 0.5mg finasteride for hair loss, noting initial side effects like sore nipples that resolved after adjusting the dosage. Other users discuss their experiences with finasteride, including effects on libido and the trade-offs of using the medication.

The conversation discusses skepticism about Breezula, a hair loss treatment, with the consensus that it's not a miracle cure but a maintenance drug that may work well with finasteride. Some users report side effects from finasteride, like sexual dysfunction, while hoping for better results from Breezula or RU58841 without such side effects.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The conversation humorously discusses the exaggerated effects of taking a 500mg pill of dutasteride, with users joking about extreme side effects like excessive hair growth and loss of sensation. It also mentions personal experiences with finasteride and the potential high bioavailability of dutasteride in liquid form.